People in the News

People in the News

(Page
1
of
1)

Click Image To Enlarge +

Archie Cullen

Archie Cullen is now president of BioReliance by SAFC. Formerly, he was vp of SAFC. Cullen also served as vp of sales for SAFC where he was promoted from vp, commercial and technical operations for the company’s biosciences business unit. His career also includes time with Life Technologies and JRH Biosciences.

Chimerix named Ernest Mario, Ph.D., chairman of its board of directors...Crocus Technology hired Ken Mackay, Ph.D., as vp of technology development...A.P. Pharma added Jesse Hollingsworth as vp of sales...Mark McDonough is now CEO at CombiMatrix...Ralf Huss, M.D., Ph.D., is now CMO at Definiens.

Click Image To Enlarge +

Yvan Sergeant

Trinean hired Yvan Sergeant as vp, commercial operations. Prior to joining Trinean, he was director of genomic applications & NGS Europe at PerkinElmer. Previously, he was managing sales and business development at Zymark. He was also managing director of Caliper LS.

Adam Moorhouse joined Onyx as a director of business development...Synthetic Biologics appointed Brad Spellberg, M.D., to its scientific advisory board...Celsus Therapeutics hired Gur Roshwalb, M.D., as CEO...Nano Labs named Patrick Barnabe, M.D., to its strategic advisory board.

Click Image To Enlarge +

Edward Owens

Ironwood Pharmaceuticals named Edward Owens to its board of directors. Most recently, he was partner, portfolio manager, and global industry analyst at Wellington Management. Owens also launched and served as portfolio manager for Vanguard Health Care Fund.

Ali Fattaey, Ph.D., joined Curis as president and COO...Amyris hired Zanna McFerson as CBO...Blueprint Medicines appointed David Schenkein, M.D., to its board of directors...Rheonix added Steve Pemberton as vp of marketing and sales and Bryan Greene as director of consumable manufacturing...INC Research promoted Garth Tierney to evp, Asia/Pacific...Accelerate Diagnostics named Frank J. M. ten Brink to its board of directors...Tissue Culture Biologicals hired James D. Titus as their new vp of sales.

Click Image To Enlarge +

Katrine Bosley

Galapagos appointed Katrine Bosley to its board of directors as an independent nonexecutive director. Formerly, she was CEO of Avila Therapeutics. Prior to Avila, Bosley was vp business development at Adnexus Therapeutics. Before that, she was in business development and commercial operations at Biogen Idec.

Bernardino Mosquera, M.D., is now vp of clinical operations at Catalyst Pharmaceutical...TB Alliance appointed David Norton to its board of directors...Nucelis added Sean O’Connor as president and CEO...Fibrocell Science named Douglas J. Swirsky to its board of directors...PharmaEngine elected Alain Herrera, M.D., as senior advisor...Nativis appointed Chris Rivera to its board of directors...Steven Kesten, M.D., joined Cytori Therapeutics as evp and CMO.

Click Image To Enlarge +

Warren Lammert

IntelliMedix appointed Warren Lammert to its board of advisors. Lammert is chairman and co-founder of the Epilepsy Therapy Project. He is also founder, principal, and chief investment officer of Granite Point Capital. Previously, he held investment and senior management roles at Janus.

Mark Carnegie-Brown, Ph.D., is now CEO at Glide Pharma...Sucampo Pharmaceuticals appointed Barbara A. Munder and Maureen E. O’Connell to its board of directors...Nanobiosym named Robert Langer, M.D., to its scientific advisory board...Curetis added Helmut Hilbert as head of business development...Michael Tomsicek is now svp and CFO at Cubist Pharmaceuticals...Greatbatch appointed Joseph W. Dziedzic to its board of directors...Michael Hickey joined Delta Point as svp of global leadership development...Capricor hired Anthony Davies, Ph.D., as chief technology officer.

Click Image To Enlarge +

Douglas Francis, Ph.D.

Clinical Network Services hired Douglas Francis, Ph.D., as senior regulatory toxicologist. Most recently, Dr. Francis offered regulatory toxicology services through his own consultancy, DF Pre-clinical Services. Previously, he was the vp of drug development at Phylogica.

Mark Erlander, Ph.D., is now CSO at Trovagene...Creabilis named Catherine Moukheibir to its board of directors...Frank Ternes is now CBO at Rentschler Biotechnologie...Caris Life Sciences added Joachim Schorr, Ph.D., as CSO...Aquavit Pharmaceuticals hired David Shafer, M.D., as chief medical technology officer...Biocell Labs appointed Paula Brown, Ph.D., to its board of directors...Matt Thompson joined Xyntek as vp of sales...Hospira hired Royce R. Bedward as vp, general counsel, and secretary...Verastem named Stephen Sherwin, M.D., to its board of directors.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.